| Dr David Alexander Leenen, MD | |
|
593 Eddy Street, Rhode Island Hospital, Providence, RI 02903 | |
| (401) 444-2857 | |
| (401) 444-6681 |
| Full Name | Dr David Alexander Leenen |
|---|---|
| Gender | Male |
| Speciality | Surgery |
| Location | 593 Eddy Street, Providence, Rhode Island |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407386931 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | LP03933 (Rhode Island) | Primary |
| Entity Name | Steward Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629398219 PECOS PAC ID: 2860688728 Enrollment ID: O20101119000007 |
News Archive
The Rosalind Franklin Institute today launched an ambitious new project to build the world's most advanced real-time high-speed video camera, the key to understanding new techniques that use light and sound to treat some of the most lethal forms of cancer.
Merck, a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials, today announced the global collaboration agreement with the fertility technologies expert Genea Biomedx, an Australian company, dedicated to advancing fertility science and helping couples create families. With this partnership, Merck Serono, the biopharmaceutical business of Merck, and global market leader in drugs for Assisted Reproductive Treatment (ART), receives global marketing and commercialization rights to Genea Biomedx's product portfolio.
Factors such as low bone density and previous fractures are commonly used to predict an individual's risk of experiencing a fracture over the next 10 years.
Advanced Cell Technology, Inc. announced today that the US Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application to immediately initiate a Phase I/II multicenter clinical trial using retinal cells derived from human embryonic stem cells (hESCs) to treat patients with Stargardt's Macular Dystrophy (SMD), one of the most common forms of juvenile macular degeneration in the world. The decision removes the clinical hold that the FDA had placed on the trial.
Data released today by the European Centre for Disease Prevention and Control and European Food Safety Authority reveal that antimicrobials used to treat diseases that can be transmitted between animals and humans, such as campylobacteriosis and salmonellosis, are becoming less effective.
› Verified 2 days ago
| Entity Name | Steward Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629398219 PECOS PAC ID: 2860688728 Enrollment ID: O20101119000332 |
News Archive
The Rosalind Franklin Institute today launched an ambitious new project to build the world's most advanced real-time high-speed video camera, the key to understanding new techniques that use light and sound to treat some of the most lethal forms of cancer.
Merck, a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials, today announced the global collaboration agreement with the fertility technologies expert Genea Biomedx, an Australian company, dedicated to advancing fertility science and helping couples create families. With this partnership, Merck Serono, the biopharmaceutical business of Merck, and global market leader in drugs for Assisted Reproductive Treatment (ART), receives global marketing and commercialization rights to Genea Biomedx's product portfolio.
Factors such as low bone density and previous fractures are commonly used to predict an individual's risk of experiencing a fracture over the next 10 years.
Advanced Cell Technology, Inc. announced today that the US Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application to immediately initiate a Phase I/II multicenter clinical trial using retinal cells derived from human embryonic stem cells (hESCs) to treat patients with Stargardt's Macular Dystrophy (SMD), one of the most common forms of juvenile macular degeneration in the world. The decision removes the clinical hold that the FDA had placed on the trial.
Data released today by the European Centre for Disease Prevention and Control and European Food Safety Authority reveal that antimicrobials used to treat diseases that can be transmitted between animals and humans, such as campylobacteriosis and salmonellosis, are becoming less effective.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David Alexander Leenen, MD 255 Promenade St Apt 525b, Providence, RI 02908-5789 Ph: (617) 756-3395 | Dr David Alexander Leenen, MD 593 Eddy Street, Rhode Island Hospital, Providence, RI 02903 Ph: (401) 444-2857 |
News Archive
The Rosalind Franklin Institute today launched an ambitious new project to build the world's most advanced real-time high-speed video camera, the key to understanding new techniques that use light and sound to treat some of the most lethal forms of cancer.
Merck, a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials, today announced the global collaboration agreement with the fertility technologies expert Genea Biomedx, an Australian company, dedicated to advancing fertility science and helping couples create families. With this partnership, Merck Serono, the biopharmaceutical business of Merck, and global market leader in drugs for Assisted Reproductive Treatment (ART), receives global marketing and commercialization rights to Genea Biomedx's product portfolio.
Factors such as low bone density and previous fractures are commonly used to predict an individual's risk of experiencing a fracture over the next 10 years.
Advanced Cell Technology, Inc. announced today that the US Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application to immediately initiate a Phase I/II multicenter clinical trial using retinal cells derived from human embryonic stem cells (hESCs) to treat patients with Stargardt's Macular Dystrophy (SMD), one of the most common forms of juvenile macular degeneration in the world. The decision removes the clinical hold that the FDA had placed on the trial.
Data released today by the European Centre for Disease Prevention and Control and European Food Safety Authority reveal that antimicrobials used to treat diseases that can be transmitted between animals and humans, such as campylobacteriosis and salmonellosis, are becoming less effective.
› Verified 2 days ago
Aileen Hsueh, Surgery Medicare: Not Enrolled in Medicare Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-444-8450 Fax: 401-444-5088 | |
Liudmila Muraveika, Surgery Medicare: Not Enrolled in Medicare Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-444-5180 Fax: 401-444-6681 | |
Todd S Stafford, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 195 Collyer St Ste 302, Providence, RI 02904 Phone: 401-228-0633 Fax: 401-793-5171 | |
Sagar Mulay, Surgery Medicare: Medicare Enrolled Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-444-5180 Fax: 401-444-6681 | |
Dewahar Senthoor, MD Surgery Medicare: Medicare Enrolled Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-444-5471 Fax: 401-444-4557 | |
Chibueze Nwaiwu, MD Surgery Medicare: Medicare Enrolled Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-444-5471 Fax: 401-444-4557 | |
Dr. Robert Ira Wolf, MD Surgery Medicare: Medicare Enrolled Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-444-5180 |